Recent developments in the field of A2A and A3 adenosine receptor antagonists

European Journal of Medicinal Chemistry

Volumn 38, Issue 4, 2003, Pages 367-382

  Baraldi, Pier Giovanni ^a   Tabrizi, Mojgan Aghazadeh ^a   Bovero, Andrea ^a   Avitabile, Barbara ^a   Preti, Delia ^a   Fruttarolo, Francesca ^a   Romagnoli, Romeo ^a   Varani, Katia ^a   Borea, Pier Andrea ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

A2A adenosine receptors; A3 adenosine receptors; Antagonists; Water solubility

Indexed keywords

5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 5 AMINO 2 (2 FURYL) 7 (3 PHENYLPROPYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 8 (3,4 DIMETHOXYSTYRYL) 7 METHYL 1,3 DIPROPYLXANTHINE; 9 CHLORO 2 (2 FURYL) 5,6 DIHYDRO 5 IMINO 1,2,4 TRIAZOLO[2,3 C]QUINAZOLINE; ADENOSINE A2A RECEPTOR ANTAGONIST; ADENOSINE A3 RECEPTOR ANTAGONIST; ISTRADEFYLLINE; PYRAZOLO[4,3 E] 1,2,4 TRIAZOLO[1,5 C]PYRIMIDINE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

CONFERENCE PAPER; DRUG RESEARCH; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROPHOBICITY;

EID: 0038394374     PISSN: 02235234     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0223-5234(03)00042-4     Document Type: Conference Paper

References (74)

1. Fredholm B.B., Arslan G., Haldner L., Kull B., Schulte G., Wasserman W. Structure and function of adenosine receptors and their genes. Naunyn-Schmied. Arch. Pharmacol. 362:2000;364-374.
2. Fredholm B.B., Ijzerman A.P., Jacobson K.A., Klotz K.-N., Linden J. Nomenclature and classification of adenosine receptors. Pharm. Rev. 53:2001;527-552.
3. Ferrè S., Fredholm B.B., Morelli M., Popoli P., Fuxe K. Adenosine-dopamine receptor-receptor interaction as an integrative mechanisms in the basal ganglia. Trends Neurosci. 20:1997;482-487.
4. 3H]-CGS 21680 binding. Br. J. Pharmacol. 117:1996;1693-1701.
5. 3H]-SCH 58261 binding. Br. J. Pharmacol. 122:1997;386-392.
6. 2A adenosine receptors in human neutrophil membranes. Br. J. Pharmacol. 123:1998;1723-1731.
7. 2A adenosine receptors in human peripheral blood cells. Br. J. Pharmacol. 129:2000;2-11.
8. Elenkov I.J., Chrousos G.P., Wilder R.L. Neuroendocrine regulation of IL-2 and TNF-alpha/IL-10 balance, clinical implications. Ann. N.Y. Acad. Sci. 917:2000;94-105.
9. 2A receptor antagonism, Seventh International Symposium on Adenosine and Adenine Neucleotides, Gold Coast Australia 2002, Abstracts Book, 109.
10. 2A adenosine recepto antagonists. Curr. Med. Chem. 2:1995;707-722.
11. 2A adenosine receptor antagonist. J. Med. Chem. 41:1998;2126-2133.
12. 2A adenosine receptor antagonists: a study on the importance of modifications at the side chain on the activity and solubility. J. Med. Chem. 45:2002;115-126.
13. 2A adenosine receptor antagonist. J. Labeled Compd. Radiopharm. XXXVIII:1996;725-732.
14. 2A adenosine receptor antagonist to rat striatal membranes. Br. J. Pharmacol. 117:1996;1381-1386.
15. 2A adenosine receptor antagonists. Drug Dev. Res. 42:1997;63-70.
16. 2A adenosine receptor antagonists in relevant rodent models. Drug Dev. Res. 50:2000;70.
17. 2A adenosine receptors: an apparent paradox. Drug Dev. Res. 45:1998;387-393.
18. Abbracchio M.P., Cattabeni F. Brain adenosine receptors as a target for therapeutic intervention in neurodegenerative disease. Ann. N.Y. Acad. Sci. 890:1999;79-92.
19. 2A receptor antagonist, on quinpirole-induced turning in 6-hydroxydopamine-lesioned rats. Lack of tolerance after chronic caffeine intake. Neuropsychopharmacology. 22:2000;522-529.
20. 2A receptor signalling in striatal cells expressing mutant huntingtin. FASEB J. 5:2001;1245-1247.
21. 3 adenosine receptors. Mol. Pharmacol. 57:2000;968-975.
22. 2A receptor agonists and antagonists. Neuroscience. 85:1998;229-237.
23. 2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats. Neuroreport. 9:1998;3955-3959.
24. Tsuruta S., Kimura M., Yoshida T. The effects of adenosine and its antagonists on elastase release from human neutrophils. Drug Dev. Res. 50:2000;53.
25. 3 adenosine receptor. Mol. Pharmacol. 57:2000;539-545.
26. 3 adenosine receptors: design of selective ligands and therapeutic prospects. Drugs Future. 20:1995;689.
27. 3 adenosine receptors on human eosinophils elevates intracellular calcium. Blood. 88:1996;3569.
28. 3 receptor stimulation and cerebral ischemia. Eur. J. Pharmacol. 263:1994;59.
29. 3 receptor agonist and cerebral ischemia: neuronal and glial effects. Eur. J. Pharmacol. 367:1999;157.
30. 3 receptors: novel ligands and paradoxical effects. Trends Pharmacol. Sci. 19:1998;184.
31. 3 receptor-mediated hypotension in the rat. Br. J. Pharmacol. 115:1995;945.
32. 3 receptor: sustained cardioprotection. Proc. Natl. Acad. Sci. USA. 95:1998;6995.
33. Liang B.T., Jacobson K.A. Distinctive cardioprotective effects of adenosine mediated by differential coupling of receptor subtypes to phospholipases C and D. Drug Dev. Res. 50:2000;26.
34. 3 adenosine receptors: protective damaging effects identified using novel agonists and antagonists. Drug Dev. Res. 45:1998;113.
35. 3 adenosine receptors: new targets for cancer therapy and chemoprotection. Drug Dev. Res. 50:2000;101.
36. 3 adenosine receptor. Proc. Natl. Acad. Sci. USA. 90:1993;10365-10369.
37. 3 adenosine receptors in human neutrophils and promyelocytic HL60 cells: a pharmacological and biochemical study. Mol. Pharmacol. 61:2002;415-424.
38. Klotz K.N., Hessling J., Hegler J., Owman C., Kull B., Fredholm B.B., Lohse M.J. Comparative pharmacology of human adenosine receptor subtype. Characterization of stably transfected receptors in CHO cells. Naunyn-Schmied. Arch. Pharmacol. 357:1998;1-9.
39. Jacobson K.A., Suzuki F. Recent developments in selective agonists and antagonists acting at purine and pyrimidine receptor. Drug Dev. Res. 39:1996;289.
40. 3 receptors subtype. J. Med. Chem. 41:1998;2835-2845.
41. 3 adenosine receptor antagonists. J. Med. Chem. 39:1999;2293-2301.
42. 3 adenosine receptor antagonists. J. Med. Chem. 42:1999;4474-4478.
43. 8 pyrazolo nitrogen. J. Med. Chem. 43:2000;4768-4780.
44. 3 adenosine receptor ligands: histrory and perspectives. Med. Res. Rev. 2:2000;103-128.
45. 3 adenosine receptor. Drug Dev. Res. 52:2001;406-415.
46. 3 adenosine receptor antagonists. J. Med. Chem. 45:2002;770-780.
47. 3 adenosine receptor. Biochem. Pharmacol. 2002;157-161.
48. Merighi S., Varani K., Gessi S., Cattabriga E., Iannotta V., Uloglou C., Leung E., Borea P.A. Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line. Br. J. Pharmacol. 134:2001;1215-1226.
49. Merighi S., Mirandola P., Milani D., Varani K., Gessi S., Klotz K.N., Leung E., Baraldi P.G., Borea P.A. Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells. J. Invest. Dermat. 119:(4):2002;923-933.
50. 3 receptor antagonists. TIPS. 21:2001;456.
51. 2 antagonists. J. Med. Chem. 36:1992;2342-2345.
52. Müller C.E., Stein B. Adenosine receptor antagonists: structures and potential terapeutic applications. Curr. Pharm. Des. 2:1996;501-530.
53. 2-adenosine antagonist in vitro and in vivo. FEBS Lett. 323:(1-2):1993;141-144.
54. 2A receptor antagonist in MPTP-treated monkeys. Neurology. 52:1999;1673-1677.
55. 2A antagonist: a novel antiparkinsonian that does not provoked dyskinesia in parkinsonian monkeys. Ann. Neurol. 43:1998;507-513.
56. Müller C.E., Stein B. Adenosine receptor antagonist: structures and potential therapeutic applications. Curr. Pharm. Des. 2:1996;501.
57. Seale T.W., Abla K.A., Shamim M.T., Carney J.M., Daly J.W. Life Sci. 43:1988;1671.
58. 2A-selective adenosine receptor antagonists. J. Med. Chem. 40:1997;4396-4405.
59. 2A-selective adenosine receptor antagonists. Bioorg. Med. Chem. 6:1998;707-719.
60. 2A-selective adenosine receptor antagonists. J. Med. Chem. 43:2000;440-448.
61. Ongini E., Dionisotti S., Gessi S., Irenius E., Fredholm B.B. Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors. Naunyn-Schmied. Arch. Pharmacol. 359:1999;7-10.
62. 2A adenosine antagonists. J. Med. Chem. 39 (1996) 1164-1171.
63. 2A adenosine receptor antagonist. J. Pharmacol. Exp. Ther. 276:1996;398-404.
64. 2A selective adenosine receptor antagonist. Br. J. Pharmacol. 115:1995;1096-1102.
65. 1 receptors. Arch. Pharm. Pharm. Med. Chem. 332:1999;39-41.
66. 3-adenosine receptor antegonists. J. Med. Chem. 45:2002;3440-3450.
67. 3 adenosine receptors. J. Med. Chem. 39:1996;802-806.
68. Palczewski K., Kumasaka T., Hori T., Behnke C.A., Motoshima H., Fox B.A., Tong I.L., Teller D.C., Okada T., Stenkamp R.E., Yamamoto M., Miyano M. Crystal structure of Rhodopsin: a G-protein-coupled receptor. Science. 289:2000;739.
69. 3 adenosine receptor antagonist. J. Med. Chem. 45:2002;3579-3582.
70. 3 adenosine receptor and molecular modeling studies. J. Med. Chem. 44:2001;2735-2742.
71. 3 receptor subtype. J. Med. Chem. 39:1996;4142-4148.
72. 3 adenosine receptors. Bioorg. Med. Chem. Lett. 10:2000;209-211.
73. 50) of an enzymatic reaction. Biochem. Pharmacol. 22:1973;3099-3108.
74. Munson P.J., Rodbard D. Ligand: a versatile computerized approach for the characterization of ligand binding systems. Anal. Biochem. 107:1980;220-239.